by Maria Zannes | Oct 14, 2021 | Press Releases
Reveles leads CyPath® Lung, a non-invasive and highly accurate test for lung cancer, as it enters the market OCTOBER 14, 2021 (SAN ANTONIO, TX) bioAffinity Technologies today announced that Xavier T. Reveles, MS, CG, has been promoted to Vice President of Operations....
by Maria Zannes | Sep 23, 2021 | Press Releases
Australian Patent Office Issues Notice of Acceptance for Patent Related to Porphyrin Compounds and Compositions to Treat Cancer SEPTEMBER 23, 2021 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held biotech company, announced that the Australian Patent Office...
by Maria Zannes | Sep 14, 2021 | Press Releases
CyPath® Lung, an Innovative Lung Cancer Diagnostic, Fully Validated as a Laboratory Developed Test (LDT) by CAP/CLIA-Certified Laboratory SEPTEMBER 9, 2021 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held biotech company advancing innovative cancer...
by Maria Zannes | Aug 12, 2021 | Press Releases
AUGUST 12, 2021 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held company focused on early diagnostics and cancer therapeutics, announced publication in the peer-reviewed Journal of Visualized Experiments (JoVE). The paper, entitled Quality-Controlled...
by Maria Zannes | Jun 23, 2021 | Events, Press Releases
JUNE 23, 2021 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held biotech company, will present the Company’s discoveries in the field of cancer diagnostics and therapeutics at the RNA Therapeutics Institute’s 2021 RNA Therapeutics Symposium June 23 – 25,...
by Maria Zannes | Mar 3, 2021 | Press Releases
MARCH 3, 2021 (SAN ANTONIO, TX) Peer-Reviewed Paper Explains How Porphyrins Used in Company’s Diagnostic and Therapeutic Platforms Enter Cancer Cells bioAffinity Technologies, a privately held company focused on early diagnostics and cancer therapeutics, announced...
